Detalhe da pesquisa
1.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
J Antimicrob Chemother
; 75(3): 648-655, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873746
2.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23830355
3.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734016
4.
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Patient
; 15(1): 131-143, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180035
5.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
AIDS
; 36(11): 1511-1520, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466963
6.
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.
Ann Intern Med
; 153(6): 349-57, 2010 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20855799
7.
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.
HIV Res Clin Pract
; 23(1): 9-14, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34913844
8.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
J Acquir Immune Defic Syndr
; 88(1): 86-95, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397746
9.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Lancet HIV
; 7(6): e389-e400, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504574
10.
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
J Acquir Immune Defic Syndr
; 82(3): 321-328, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31609930
11.
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet HIV
; 6(6): e355-e363, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068270
12.
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Antivir Ther
; 24(6): 425-435, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355775
13.
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
J Acquir Immune Defic Syndr
; 94(3): e9-e12, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850985
14.
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
J Acquir Immune Defic Syndr
; 78(2): 209-213, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481486
15.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Lancet HIV
; 4(12): e536-e546, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729158
16.
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Lancet HIV
; 3(9): e410-e420, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27562742
17.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antivir Ther
; 20(3): 343-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25321146
18.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26201299
19.
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
J Int AIDS Soc
; 17(4 Suppl 3): 19532, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394041
20.
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.
J Womens Health (Larchmt)
; 20(7): 1043-50, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21663416